The online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter, is available for STAT+ subscribers to receive in their inbox. The newsletter includes updates on Novartis’ pelabresib from its earnings announcement. The delivery was delayed due to the heat, but the update is the lead item in the newsletter. Subscribers can continue to STAT+ to read the full story.
Source link
STAT+: Novartis not ready to admit a $3 billion mistake
